The name of the UK NEQAS for GFR Estimations Scheme has been changed to UK NEQAS for Acute and Chronic Kidney Disease to include the newly accredited analyte AKI. You can participate in either, or both, the AKI and CKD elements of the Scheme.

Due to the nature of the AKI element of the Scheme which looks at historical data, there will be, by necessity, restricted time points where you can join. New participants to this Scheme will be able to join:

  • Up to 1st July 2022 and will receive specimens from Distribution 189
  • Up to 1st October 2022 and will receive specimens from Distribution 192
  • Up to 1st January 2023 and will receive specimens from Distribution 195

Please contact Birmingham Quality if you have any questions or view our AKI presentation for more information.

Scheme Particulars Indicative Details
Accreditation body UKAS
UKAS Accredited Proficiency Testing Provider No 7860
Number of distributions per year (nominal) 11
Specimens per distribution 3 (Separate specimens for Creatinine for eGFR, Creatinine for AKI and Cystatin C)
Frequency of distribution Monthly
Material distributed Pooled, liquid human serum with or without exogenous added analyte
Nominal sample volume (mL) 0.5 (0.25 mL Cystatin C)
Programme Director(s) / Organiser(s) Finlay MacKenzie
Analyte Approximate Range Default Scheme Units
AKI stage AKI stage 1,2,3 and all other flags
Cystatin C 0 – 10 mg/L
eGFR 2009 CKD-EPI SCr 10 – >90 mL/min/1.73m2
eGFR CKD-EPI Cys 10 – >90 mL/min/1.73m2
eGFR MDRD 10 – >90 mL/min/1.73m2
expected eGFR 2009 CKD-EPI SCr 10 – >90 mL/min/1.73m2
expected eGFR CKD-EPI Cys 10 – >90 mL/min/1.73m2
expected eGFR MDRD 10 – >90 mL/min/1.73m2
Serum creatinine - AKI 25 – 500 µmol/L
Serum creatinine - CKD 25 – 500 µmol/L
  • Download Acute and Chronic Kidney Disease 2022 schedule 37 KB

Last Updated: